Immune control and genomic instability at micronuclei
Project Number5R37CA261183-02
Former Number1R01CA261183-01A1
Contact PI/Project LeaderMACIEJOWSKI, JOHN
Awardee OrganizationSLOAN-KETTERING INST CAN RESEARCH
Description
Abstract Text
PROJECT SUMMARY
Chromosomal instability (CIN) is a hallmark of cancer characterized by high rates of chromosome mis-segre-
gation during cell division. CIN can generate nuclear aberrations termed micronuclei when a chromosome or
chromosome fragment lags during anaphase and fails to join the main chromatin mass that will form the prima-
ry nucleus. Micronuclei recruit nuclear envelopes but defects in construction lead to frequent rupturing, loss of
compartmentalization, and an unregulated exchange of proteins and small vesicles with the cytoplasm. Mi-
cronuclear envelope rupturing causes broad dysfunction and is associated with extensive DNA damage and
genomic rearrangements, including clustered mutational phenomena such as chromothripsis and kataegis,
which are commonly observed in cancer genomes. Ruptured micronuclei can also activate the pro-inflammato-
ry cGAS-STING pathway, which plays essential roles in anti-tumor immunity. These observations suggest that
micronuclei may represent key platforms for genome evolution and immune activation in cancer. The mecha-
nisms driving DNA damage and immune activation at micronuclei are poorly understood. The laboratory dis-
covered that the endoplasmic reticulum (ER)-associated exonuclease TREX1, which is mutated in a variety of
human immune diseases including Aicardi-Goutières Syndrome, accumulates at micronuclei upon micronu-
clear envelope rupture where it resects micronuclear DNA and limits cGAS-STING activation. Therefore,
TREX1 occupies central positions in key pathways with diverse roles in human health and disease. Conse-
quently, there is strong rationale to understand mechanisms of TREX1 activity and engagement with cytosolic
DNA. The long-term goals of the laboratory are to determine mechanisms of DNA damage, clustered mutage-
nesis, and immune activation at sites of nuclear envelope rupture. The specific Aims of this proposal are to 1)
Elucidate mechanisms of TREX1 structure and function, 2) Determine how TREX1 is recruited to micronuclei,
and 3) Dissect pathways of micronuclear DNA damage. Each objective is supported by extensive preliminary
data. Aim 1 will focus on a previously uncharacterized region in TREX1, which is essential for its ability to de-
grade cytosolic DNA and inhibit cGAS activation. Aim 2 will build on results showing that TREX1 DNA binding
function is dispensable for its localization to micronuclei, while its association with the ER is essential. Aim 3
will use a new method to purify micronuclei to dissect sources of micronuclear DNA damage. Taken together,
these data will provide fundamental insights into cancer genome evolution, explain how previously uncharac-
terized TREX1 mutations cause Aicardi-Goutières syndrome, and may identify new strategies to improve anti-
tumor immunity.
Public Health Relevance Statement
PROJECT NARRATIVE
Micronuclei are aberrant nuclear compartments that can form as a result of chromosome mis-segregation.
Frequent loss of micronuclear envelope integrity exposes DNA to the cytoplasm, leading to genomic DNA re-
arrangements and immune activation. Building on our prior work, we now propose to determine the mecha-
nisms of DNA damage and immune activation at micronuclei.
No Sub Projects information available for 5R37CA261183-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R37CA261183-02
Patents
No Patents information available for 5R37CA261183-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R37CA261183-02
Clinical Studies
No Clinical Studies information available for 5R37CA261183-02
News and More
Related News Releases
No news release information available for 5R37CA261183-02
History
No Historical information available for 5R37CA261183-02
Similar Projects
No Similar Projects information available for 5R37CA261183-02